InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (5 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
5
T+90 hit rate
100%
T+90 mean return
+12.7%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Friedl-Naderer Johanna, Directeur Commercial. Insider active across 2 companies, notably Dyne Therapeutics, Inc.. Aggregated, 9 reports have been published. Breakdown: 0 buy · 5 sells. Total volume traded: €41k. History available since 2 March 2022. The latest transaction was disclosed on 13 May 2026 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations9 total
145 sharesCommon StockSEC:0001915598-26-000002:0
228 shares@ US$18.360.0001% mcap50.0% of flowCommon StockSEC:0001193125-26-223984
228 shares@ US$18.360.0001% mcap50.0% of flowCommon StockSEC:0001193125-26-223984:0
143 shares@ US$12.1218.2% of flowCommon StockSEC:0000950170-25-038750:0
37,800 shares0Common StockSEC:0000950170-24-134078:0
58,400 shares0Common StockSEC:0000950170-24-103033:0
1,482 shares@ US$22.82100.0% of flowCommon StockSEC:0001209191-23-016629:0
60,000 shares0Common StockSEC:0001209191-23-012991:0
90,000 shares0Common StockSEC:0001209191-22-016929:0
9 of 9 declarations
About Friedl-Naderer Johanna
Johanna Friedl-Naderer is the Chief Commercial Officer and Chief Business Officer, Global at Dyne Therapeutics, Inc. and Vir Biotechnology, Inc. She is responsible for commercial strategy and international business direction for these biopharmaceutical companies. Her expertise in the commercial field contributes to the expansion and innovation of health products.
